A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders

For a naïve patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries.